BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 33042272)

  • 21. USP18 reduces paclitaxol sensitivity of triple-negative breast cancer via autophagy.
    Ge X; Zhang D; Song S; Mi Y; Shen Y; Jiang Q; Liang Y; Wang J; Ye Q
    Biochem Biophys Res Commun; 2022 Apr; 599():120-126. PubMed ID: 35180471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.
    Sato K; Padgaonkar AA; Baker SJ; Cosenza SC; Rechkoblit O; Subbaiah DRCV; Domingo-Domenech J; Bartkowski A; Port ER; Aggarwal AK; Ramana Reddy MV; Irie HY; Reddy EP
    Nat Commun; 2021 Aug; 12(1):4671. PubMed ID: 34344863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
    Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
    Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel combinatorial autophagy inhibition therapy for triple negative breast cancers.
    Abd El-Aziz YS; Toit-Thompson TD; McKay MJ; Molloy MP; Stoner S; McDowell B; Moon E; Sioson L; Sheen A; Chou A; Gill AJ; Jansson PJ; Sahni S
    Eur J Pharmacol; 2024 Jun; 973():176568. PubMed ID: 38604544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer.
    Liang Z; Feng A; Shim H
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):413-423. PubMed ID: 31907648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Na⁺/H⁺ exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells.
    Amith SR; Wilkinson JM; Baksh S; Fliegel L
    Oncotarget; 2015 Jan; 6(2):1262-75. PubMed ID: 25514463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
    Zheng S; Li M; Miao K; Xu H
    J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
    Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
    Chou CW; Huang YM; Chang YJ; Huang CY; Hung CS
    Int J Med Sci; 2021; 18(12):2521-2531. PubMed ID: 34104083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
    Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
    Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
    Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
    Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
    Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
    Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
    Giordano A; Liu Y; Armeson K; Park Y; Ridinger M; Erlander M; Reuben J; Britten C; Kappler C; Yeh E; Ethier S
    PLoS One; 2019; 14(11):e0224420. PubMed ID: 31751384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
    Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
    Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.